MEIHUA BIO、MeiHua Group(SH:600873) GUOTAI HAITONG SECURITIES·2025-10-23 13:16Investment Rating - The investment rating for the company is "Accumulate" with a target price of 13.44 CNY [4][12]. Core Insights - The report highlights that the consolidation of Xiehe Fermentation will enhance earnings, with an expected increase in non-recurring gains of approximately 780 million CNY in the 2025 profit statement [12]. - The company is adapting to global competitive pressures by actively engaging in international trade negotiations, successfully reducing the EU anti-dumping tax rate on lysine from an initial 84.8% to a final rate of 47.7%, thereby improving price competitiveness [12]. - The company is accelerating its overseas capacity expansion, having completed the acquisition of Xiehe Fermentation's related businesses in Japan, which allows for an extension into high-value-added pharmaceutical-grade amino acids and enhances its international operational footprint [12]. Financial Summary - The total revenue for 2023 is projected at 27,761 million CNY, with a slight decrease of 0.6% compared to the previous year. The net profit attributable to the parent company is expected to be 3,181 million CNY, reflecting a significant decline of 27.8% [11]. - For the years 2025 to 2027, the net profit is forecasted to be 3,200 million CNY, 3,456 million CNY, and 3,728 million CNY respectively, indicating a recovery trend with growth rates of 16.8%, 8.0%, and 7.9% [11]. - The company maintains a net asset return rate of 22.5% for 2023, which is expected to decrease to 18.8% in 2024 before stabilizing around 19.3% by 2027 [11]. Market Data - The company's market capitalization is approximately 29,921 million CNY, with a 52-week stock price range of 9.14 to 11.65 CNY [5]. - The current price-to-earnings ratio is 9.41, which is projected to decrease to 8.03 by 2027, indicating a potential undervaluation compared to industry peers [11][14].